Evidence map›Paper›PMID 33732983›Full record

ArticleKidney international reports2021

The Associations of Plasma Biomarkers of Inflammation With Histopathologic Lesions, Kidney Disease Progression, and Mortality-The Boston Kidney Biopsy Cohort Study.

Anand Srivastava, Insa M Schmidt, Ragnar Palsson, Astrid Weins, Joseph V Bonventre, Venkata Sabbisetti, Isaac E Stillman, Helmut G Rennke, Sushrut S Waikar

Open access · goldAbstract read
In one paragraph

Article in Kidney international reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.

  1. Urinary Biomarkers and Kidney Injury in VA NEPHRON-D: Phenotyping Acute Kidney Injury in Clinical Trials.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2024
    Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Evaluation of Plasma Biomarkers to Predict Major Adverse Kidney Events in Hospitalized Patients With COVID-19.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2023
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 2 countries.

Anand SrivastavaCenter for Translational Metabolism and Health, Institute for Public Health and Medicine, Division of Nephrology and Hypertension, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Insa M SchmidtSection of Nephrology, Boston University School of Medicine and Boston Medical Center, Boston, Massachusetts, USA.
Ragnar PalssonRenal Division, Brigham & Women's Hospital, Boston, Massachusetts, USA.
Astrid WeinsPathology Department, Brigham & Women's Hospital, Boston, Massachusetts, USA.
Joseph V BonventreRenal Division, Brigham & Women's Hospital, Boston, Massachusetts, USA.
Venkata SabbisettiRenal Division, Brigham & Women's Hospital, Boston, Massachusetts, USA.
Isaac E StillmanDepartment of Pathology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Helmut G RennkePathology Department, Brigham & Women's Hospital, Boston, Massachusetts, USA.
Sushrut S WaikarSection of Nephrology, Boston University School of Medicine and Boston Medical Center, Boston, Massachusetts, USA.
Brigham and Women's Hospital · USBeth Israel Deaconess Medical Center · USBoston Medical Center · USBoston University · USNational University Hospital of Iceland · ISNorthwestern University · US

Funding

Harvard Clinical and Translational Science CenterUL1TR001102 · NCATS · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2013 to 2017
$106.2M
KIDNEY INJURY MOLECULE-1 IN EPITHELIAL REPAIRR01DK072381 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI BONVENTRE, JOSEPH VINCENT · 2005 to 2025
$8.6M
Therapeutics Development Core (Core B)P30DK114857 · NIDDK · NORTHWESTERN UNIVERSITY AT CHICAGO · PI GEORGE, ALFRED L., QUAGGIN, SUSAN E. · 2018 to 2022
$5.7M
Urinary Biomarkers of Chronic Kidney Disease Pathology and ProgressionU01DK085660 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI BONVENTRE, JOSEPH VINCENT, WAIKAR, SUSHRUT S. · 2009 to 2019
$5.3M
Mechanisms of Ischemic Kidney Injury and RepairR37DK039773 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI BONVENTRE, JOSEPH VINCENT · 1993 to 2021
$5.2M
Kidney Microphysiological Analysis Platforms (MAP) to Optimize Function and Model DiseaseUH3TR002155 · NCATS · BRIGHAM AND WOMEN'S HOSPITAL · PI BONVENTRE, JOSEPH VINCENT, LEE, LUKE P. · 2019 to 2021
$3.3M
Biomarkers of Kidney PathologyR01DK093574 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI WAIKAR, SUSHRUT S. · 2012 to 2015
$2.4M
Novel Human Biomarkers of Kidney FibrosisU01DK104308 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI HUMPHREYS, BENJAMIN D., WAIKAR, SUSHRUT S. · 2014 to 2018
$2.0M
Oxalate and the Progression and Complications of CKDR01DK103784 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI WAIKAR, SUSHRUT S. · 2015 to 2018
$1.6M
Non-Invasive Imaging Biomarkers to Identify a High-Risk Chronic Kidney Disease PhenotypeK23DK120811 · NIDDK · UNIVERSITY OF ILLINOIS AT CHICAGO · PI SRIVASTAVA, ANAND · 2020 to 2024
$1.0M
Harvard Chronic Kidney Disease Research Biopsy CenterUH3DK114915 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI ROSAS, SYLVIA E, WAIKAR, SUSHRUT S. · 2019 to 2021
$900k
Metabolomics and Renal Functional ReserveR21DK119751 · NIDDK · BOSTON MEDICAL CENTER · PI WAIKAR, SUSHRUT S. · 2019 to 2020
$503k
NCATS NIH HHS UH3 TR002155NCATS NIH HHS UL1 TR001102NIDDK NIH HHS K23 DK120811NIDDK NIH HHS P30 DK114857NIDDK NIH HHS R01 DK072381NIDDK NIH HHS R01 DK093574NIDDK NIH HHS R01 DK103784NIDDK NIH HHS R21 DK119751NIDDK NIH HHS R37 DK039773NIDDK NIH HHS U01 DK085660NIDDK NIH HHS U01 DK104308NIDDK NIH HHS UH3 DK114915
6 · The paper itself

Abstract

backgroundSoluble tumor necrosis factor receptor (sTNFR)-1, sTNFR-2, YKL-40, monocyte chemoattractant protein (MCP)-1, and soluble urokinase plasminogen activator receptor (suPAR) have emerged as promising biomarkers of inflammation but have not been evaluated across diverse types of kidney diseases.

methodsWe measured these plasma biomarkers in 523 individuals enrolled into a prospective, observational cohort study of patients undergoing clinically indicated native kidney biopsy at 3 tertiary care hospitals. Two kidney pathologists adjudicated biopsy specimens for semiquantitative scores of histopathology. Proportional hazard models tested associations between biomarkers and risks of kidney disease progression (composite of ≥40% estimated glomerular filtration rate [eGFR] decline or end-stage kidney disease [ESKD]) and death.

resultsMean eGFR was 56.4±36 ml/min per 1.73 m

conclusionssTNFR-1, sTNFR-2, YKL-40, MCP-1, and suPAR are associated with underlying histopathologic lesions and adverse clinical outcomes across a diverse set of kidney diseases.

Indexed as

biomarkerfibrosishistopathologyinflammationkidney biopsykidney disease

Identifiers

PMID33732983
PMCPMC7938082
OpenAlexW3120358270

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.